Safety and Immunogenicity in Dose-Ranging and Formulation-Finding Meningococcal B (MenB) Vaccine Study in 2-month-old Infants

Exclusion Criteria

• •Any meningococcal B or C vaccine administration
• •Prior vaccination with any Diphtheria, Tetanus, Pertussis (acellular or whole cell), Polio (either Inactivated or Oral), Haemophilus influenzae type b (Hib), and Pneumococcal antigens;
• •Any ascertained or suspected disease caused by N. meningitidis
• •Household contact with and/or intimate exposure to an individual with laboratory confirmed N. meningitidis
• •History of severe allergic reaction after previous vaccinations
• •Recent significant acute or chronic infection
• •Oral or parenteral antibiotic treatment in the 7 days prior to the scheduled blood draw;
• •Any serious chronic or progressive disease according to the judgment of the investigator (e.g., neoplasm, diabetes mellitus Type I, cardiac disease, hepatic disease, progressive neurological disease or seizure, either associated with fever or as part of an underlying neurological disorder or syndrome, autoimmune disease, HIV infection or AIDS, or blood dyscrasias or diathesis, signs of cardiac or renal failure or severe malnutrition)
• •Any impairment/alteration of the immune system resulting from (for example):
• •* Receipt of any immunosuppressive therapy at any time since birth
• •* Receipt of immunostimulants at any time since birth
• •* Use of systemic corticosteroids or chronic use of inhaled high-potency corticosteroids at any time since birth
• •Receipt of blood, blood products and/or plasma derivatives or any parenteral immunoglobulin preparation
• •Participation in another clinical trial
• •Family members and household members of research staff
• •History of seizure
• •Any contraindication to paracetamol